Gemcitabine and mitomycin C in advanced pancreatic cancer: A single-institution experience

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 575-579

  Tuinmann, Gert ^a   Hegewisch Becker, Susanna ^a   Zschaber, Reinhart ^a   Kehr, Andreas ^a   Schulz, Juliane ^a   Hossfeld, Dieter K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemotherapy; Gemcitabine; Mitomycin C; Pancreatic cancer

Indexed keywords

GEMCITABINE; MITOMYCIN C; STEROID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA; OUTPATIENT CARE; PANCREAS CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; QUALITY OF LIFE; STROKE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TUMOR GROWTH; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HOSPITALS, UNIVERSITY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3142737865     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131683.29260.d1     Document Type: Article

References (29)

1. Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Wolley 3rd PV, et al. 5-Fluorouracil, adriamycin and mitomycin C (FAM) chemotherapy for advanced adenocarcinomas of the pancreas. Cancer 1980; 46:2014-2018.
2. Bukowski RM, Balcerzak SP, O'Bryan RM, Bonnet JD, Chenn TT. Randomised trial of 5-FU and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 1983; 52:1577-1582.
3. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil and doxorubicin and mitomycin. J Am Med Ass 1985; 253:2061-2067.
4. The Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin plus fluorouracil. J Clin Oncol 1986; 57:29-33.
5. Burris HA III, Moore MJ, Anderson J, Green JA, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with GEM as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
6. Jacobs AD, Otero H, Picozzi V, Aboulafia D, Rudolph R, Weiden P, et al. Gemcitabine and taxotere in patients with unresectable pancreatic carcinoma. Proc Am Soc Clin Oncol 1999; 18:288a (abstr 1103).
7. Kakolyris S, Stathopoulos G, Tsavaris N, Andoulakis N, Kourousiss CH, Samantas E, et al. First line treatment with docetaxel and gemcitabine in patients with advanced pancreatic cancer: a multicenter phase II study. Proc Am Soc Clin Oncol 1999; 18:250a (abstr 960).
8. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, König H, Illiger HJ, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11:1399-1403.
9. Philip PA, Zapuski M, Vaitkevicius VK. Phase II study of gemcitabine an cisplatin in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 1999; 18:274a (abstr).
10. Rocha Lima CMS, Savarese D, Bruckner H, Dudek A, Eckardt J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20:1182-1191.
11. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer 2002; 95(4 suppl):928-932.
12. Feliu J, Mel R, Borrega P, Lopez Gemez L, Escudero P, Dorta J, et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/ tegafur in advanced carcinoma of the pancreas. Ann Oncol 2002; 13:1756-1762.
13. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14:97-104.
14. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment IV: pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2:193.
15. Whittington RM, Close HP. Clinical experience with mitomycin C. Cancer Chemother Rep 1970; 54:195.
16. Carter SK. Mitomycin C - clinical brochure. Cancer Chemother Rep 1968; 1:99.
17. Moore GE, Bross ID, Ausmans R, Nadler S, Jones Jr R, Slack N, et al. Effects of mitomycin C in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 1968; 52:675.
18. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002; 20:3130-3136.
19. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-3275.
20. Louvet C, Labianca R, Hammel P, Lledo G, De Braud F, Andre T, et al. Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non respectable pancreatic adenocarcinoma: interim results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 2003; 22:A1004.
21. Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar LA, Morganti A, et al. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003; 22:A1005.
22. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17:585-592.
23. Louvet C, Andre T, Hammel P, Selle F, Landi B, Cattan S, et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (Folfugem). Ann Oncol 2001; 12:675-679.
24. Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21:66-68.
25. Roa S, Cunningham D. Advanced pancreatic cancer - 5 years on. Ann Oncol 2002; 13:1165-1168.
26. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2′,2′-difluorodeoycytidine (gemcitabine) with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44:177-123.
27. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92:569-577.
28. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512-1518.
29. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. A prospective, randomised phase III study of the Truppo Oncologico dell Italia Meridionale. Cancer 2002; 94:902-910.